Navigation Links
Amarantus BioSciences Issues CEO Letter to Shareholders
Date:11/19/2012

SUNNYVALE, Calif., Nov. 19, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that President & CEO Gerald Commissiong issued a letter to shareholders as detailed below.

Dear Shareholders,

I thank you for the trust you have placed in our management team. We fully respect the value of the money you have chosen to invest in Amarantus Biosciences, selecting us over the many other investment options available. We are focused on our mission to offer meaningful products to help patients suffering from debilitating diseases, and we believe our technologies and expertise can have an impact in multiple areas.

As was recently announced, we were able to strengthen the corporation's balance sheet by raising cash and reducing liabilities. These financing transactions were vital for the Company to pay certain vendors who are critical to on-going operations, as well as raise sufficient working capital to pursue our corporate strategy, as detailed below. Our management team and Board of Directors remain extremely dedicated to the overall success of the corporation. This is evidenced by every member working without cash consideration since Amarantus became public in the spring of 2011. This has allowed all available resources to be focused on product development.

With the financing completed, we intend to expand our resources in the areas of corporate communications, regulatory affairs, and product development in order to execute upon our corporate strategy. In this effort, yesterday we received positive feedback at the CNS Summit 2012 on a presentation made by our Chief Scientist. We intend to continue to present the Company at various scientific and investor conferences in order to expose new investor
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amarantus BioSciences Secures $1.1 Million in Financing
2. Correction: Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
3. Amarantus BioSciences Updates Shareholders on Timing of Michael J. Fox Foundation Grant Data Release
4. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
5. TheStockRadio.com Interviews Amarantus BioSciences President & CEO Gerald E. Commissiong
6. Amarantus BioSciences Featured in BioWorld Today, Brewer Sports Symposium and Opportunist Magazine
7. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
8. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
10. Neurocrine Biosciences Reports Third Quarter 2012 Results
11. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... (PRWEB) August 29, 2014 Due to a ... last week, the Adult Stem Cell Technology Center, LLC ( ... support stem cell therapy research that might benefit ALS patients. ... cells for new stem cell technologies and therapeutic applications, FRC ... Ice Bucket Challenge donors who wish not to support ...
(Date:8/29/2014)... MA, San Antonio, TX (PRWEB) August 29, 2014 ... ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 ... has been awarded an international Phase II clinical ... with non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic ... including, but not limited to, protocol and charter ...
(Date:8/28/2014)... 2014 Best Sanitizers, Inc., a leader ... processing industry, is asking industry professionals to prepare for ... the E2 soap they’re currently using to the Best ... Hand hygiene is critical to fighting cross-contamination and ... Six key criteria are identified to evaluate the effectiveness ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
Breaking Biology Technology:The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... business delivers record growth; biofuels business, advancing ... Mass., May 5 Verenium Corporation,(Nasdaq: VRNM ... cellulosic,ethanol and high-performance specialty enzymes, today reported financial,results ... updated 2008 financial,guidance., "I am encouraged by ...
... 37.5% to $14.8 Million ... ... Guidance, MINNEAPOLIS, May 5 ATS Medical, Inc. (Nasdaq:,ATSI), manufacturer ... results for the first,quarter ended March 29, 2008. Revenue for the ...
... May 5 Assay Designs, Inc., a leading,provider ... life sciences,and translational research markets, announced a collaboration ... University of South Carolina and,Dr. Jennifer Isaacs, laboratory. ... provide anti-Heat shock protein 90 (Hsp90) antibody for ...
Cached Biology Technology:Verenium Reports Financial Results for the First Quarter 2008 2Verenium Reports Financial Results for the First Quarter 2008 3Verenium Reports Financial Results for the First Quarter 2008 4Verenium Reports Financial Results for the First Quarter 2008 5Verenium Reports Financial Results for the First Quarter 2008 6Verenium Reports Financial Results for the First Quarter 2008 7Verenium Reports Financial Results for the First Quarter 2008 8Verenium Reports Financial Results for the First Quarter 2008 9Verenium Reports Financial Results for the First Quarter 2008 10Verenium Reports Financial Results for the First Quarter 2008 11ATS Medical Announces Record Quarterly Revenue and Gross Profit 2ATS Medical Announces Record Quarterly Revenue and Gross Profit 3ATS Medical Announces Record Quarterly Revenue and Gross Profit 4ATS Medical Announces Record Quarterly Revenue and Gross Profit 5ATS Medical Announces Record Quarterly Revenue and Gross Profit 6ATS Medical Announces Record Quarterly Revenue and Gross Profit 7ATS Medical Announces Record Quarterly Revenue and Gross Profit 8ATS Medical Announces Record Quarterly Revenue and Gross Profit 9Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC) 2
(Date:8/28/2014)... is needed to ensure safeguards are in place to ... PLOS ONE , researchers from Monash University, Stellenbosch University ... results from different studies - to look at the ... determine whether they actually protect biodiversity. , Dr ... area from human exploitation made common sense, however, up ...
(Date:8/27/2014)... -- WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that it ... units of common stock and warrants at a price ... million, prior to deducting underwriting discounts and commissions and ... warrants are immediately separable and will be issued separately.  ... consists of 2,000 shares of common stock and 2,000 ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Law Enforcement ... http://www.reportlinker.com/p02316674/Law-Enforcement-Biometrics-Market-in-North-America-2014-2018.html About Biometrics ... individuals on the basis of their physical or ... of both physiological traits such as fingerprints, face ...
Breaking Biology News(10 mins):Protected areas proven to protect biodiversity 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3Law Enforcement Biometrics Market in North America 2014-2018 2Law Enforcement Biometrics Market in North America 2014-2018 3Law Enforcement Biometrics Market in North America 2014-2018 4Law Enforcement Biometrics Market in North America 2014-2018 5
... 20, 2011 Whether engaging experts from the outside to ... AIDS, leaders around the globe acknowledge the need to innovate ... facing business and society today. NineSigma, the leading provider of ... the imperative to innovate for organizations is greater than ever, ...
... Gulf of Mexico is safe to eat after the Deepwater ... testing program that continues more than a year after the ... by Federal agencies to assure safety of Gulf seafood is ... of Chemical & Engineering News (C&EN), ACS,s weekly news magazine. ...
... A new genus and species of hadrosaur (duck-billed) dinosaur ... has been named by scientists who expect the ... most striking feature of Acristavus gagslarsoni , the ... head lacked the distinctive ornamentation common to later duck-billed ...
Cached Biology News:NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 2NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 3NineSigma Declares "Innovate or Die" Is the Mantra for Business Success 4New duck-billed dinosaur gives scientists clues to evolution of head ornamentation and provinciality 2
Anti-Human Factor XIII HRPO (Polyclonal) (sheep IgG)...
... monoclonal [F30 P7 D7 F5] to ... tested applications). Antigen: ... Ovalbumin, corresponding to amino acids 462 ... Entrez Gene ID: 6259 ...
E2F-5...
LAB/Probe Mouse-Rabbit DAB Kit...
Biology Products: